Related Experiment Videos
Vampire bats yield potent clot buster for ischemic stroke.
Cynthia Grandjean1, Patricia C McMullen, Gregg Newschwander
1School of Nursing, The Catholic University of America, Washington, DC 20064, USA. grandjean@cua.edu
The Journal of Cardiovascular Nursing
|November 6, 2004
Summary
Desmodus rotundus plasminogen activator (DSPA), derived from vampire bat saliva, shows promise as a stroke treatment. Unlike tPA, DSPA may reduce neurotoxicity and has a wider treatment window, offering a potentially safer alternative for acute ischemic stroke patients.
Area of Science:
- Biochemistry
- Neurology
- Pharmacology
Background:
- Tissue-type plasminogen activator (tPA) is the current standard treatment for acute ischemic stroke.
- Concerns exist regarding tPA's potential for neurotoxicity and systemic effects like plasminogen consumption and fibrinogenolysis.
- A novel therapeutic agent, Desmodus rotundus plasminogen activator (DSPA), is being investigated as an alternative.
Purpose of the Study:
- To evaluate DSPA as a potential therapeutic agent for acute ischemic stroke.
- To compare the safety and efficacy profile of DSPA with tPA.
- To assess the therapeutic window and potential side effects of DSPA.
Main Methods:
- Review of animal research comparing DSPA and tPA effects on neuronal survival and systemic fibrinolysis.
- Analysis of clinical trial data from Phase II studies involving DSPA in human stroke patients.
- Ongoing Phase III clinical trials to further validate DSPA's efficacy and safety in stroke populations.
Main Results:
- Animal studies suggest DSPA exhibits neuroprotective properties and lacks the systemic effects associated with tPA.
- DSPA's fibrin-dependent activity may mitigate risks of systemic plasminogen consumption and fibrinogenolysis.
- Phase II clinical trials in humans have yielded positive outcomes, supporting DSPA's therapeutic potential.
Conclusions:
- DSPA presents a promising alternative to tPA for acute ischemic stroke treatment.
- DSPA may offer a wider therapeutic window (up to 9 hours) compared to tPA (3 hours).
- Further Phase III trials are crucial to confirm DSPA's benefits and establish its role in stroke management.